Out bought out -$68
04/01/2024 10:24:48 Sold 400 ADTH @ 3.2 1,279.92
Out never saw a reason to add. +$10
04/01/2024 13:13:43 Sold 100 NNBR @ 4.77 476.98
Now 1575 Definitely wasn't part of a plan, but SPRY falling off a high on less
than normal vol., what to do?
04/01/2024 12:00:53 Sold 100 ENPH @ 118.0601 11,805.90
04/02/2024 14:52:59 Sold 100 ENPH @ 113.8701 11,386.90
04/03/2024 13:35:39 Sold 25 ENPH @ 116.4649 2,911.60
Now 5200 +$5049 and $1993 in the bank
04/01/2024 12:03:06 Bought 1000 SPRY @ 9.58 -9,580.00
04/02/2024 14:56:19 Bought 1000 SPRY @ 9.4299 -9,429.90
04/01/2024 14:12:24 Bought 200 SPRY @ 9.52 -1,904.00
Today news:
ARS pharmaceuticals has submitted its response to the U.S. Food and Drug Administration for its New
Drug Application of neffy epinephrine nasal spray for the treatment of Type I allergic reactions including
anaphylaxis.
The submission follows receipt of a Complete Response Letter from the FDA in September 2023, which
identified two additional requests: completion of a repeat dose pharmacokinetic/pharmacodynamic study of
neffy under nasal allergen challenge (NAC) conditions, and completion of updated nitrosamine testing per
the FDA's draft guidance issued in August 2023.
In February 2024, ARS Pharma successfully completed the repeat dosing study of neffy in seasonal allergic
rhinitis under NAC conditions. ARS Pharma also completed the nitrosamine testing requested with no
measurable levels of nitrosamines detected.
The original neffy NDA was submitted in August 2022. In May 2023, the FDA Advisory Committee
determined a favorable benefit-risk profile for neffy: 16:6 for adults and 17:5 for children. No committee
member requested a repeat dose study during allergen-induced allergic rhinitis.
ARS Pharma sees an FDA review period of up to six months, and the PDUFA date is anticipated to be Oct.
2, 2024, based on the submission receipt date of April 2, 2024.
Now 500 -$115
04/01/2024 12:10:48 Bought 100 CGEN @ 2.455 -245.50
Now 475 +$93
04/02/2024 15:30:28 Bought 25 ABSI @ 5.12 -128.00
Now 415 +$88 not much for sale there
04/01/2024 15:59:57 Bought 9 FORA @ 2.86 -25.74
Now 975 +$620
04/02/2024 15:06:33 Bought 50 WVE @ 6.11 -305.50
04/03/2024 14:00:31 Bought 25 WVE @ 5.76 -144.00
Now 1075 +$2566 and $101 in the bank
04/03/2024 13:46:33 Bought 50 ADMA @ 6.3199 -316.00
New
04/03/2024 14:27:15 Bought 150 CTV @ 2.25 -337.50
New
04/02/2024 15:16:43 Bought 4 STE @ 216.05 -864.20
04/02/2024 15:30:37 Bought 3 STE @ 215.81 -647.43
Now 86 Down $386 - thought 60 was the bottom
04/02/2024 13:00:57 Bought 3 CNXC @ 62.08 -186.24
04/02/2024 13:04:26 Bought 3 CNXC @ 61.99 -185.97
04/02/2024 14:43:27 Bought 3 CNXC @ 61.81 -185.43
04/02/2024 15:43:17 Bought 3 CNXC @ 61.69 -185.07
04/02/2024 15:54:10 Bought 3 CNXC @ 61.46 -184.38
04/03/2024 10:05:00 Bought 3 CNXC @ 60.85 -182.55
04/03/2024 10:55:04 Bought 3 CNXC @ 60.47 -181.41
04/03/2024 11:08:15 Bought 3 CNXC @ 60.05 -180.15
04/03/2024 11:37:33 Bought 3 CNXC @ 59.71 -179.13
04/03/2024 12:13:16 Bought 1 CNXC @ 59.35 -59.35
04/03/2024 12:13:52 Bought 1 CNXC @ 59.35 -59.35
04/03/2024 12:13:52 Bought 1 CNXC @ 59.35 -59.35
04/03/2024 12:46:39 Bought 3 CNXC @ 58.7 -176.10
04/03/2024 13:41:17 Bought 10 CNXC @ 58.25 -582.50
04/03/2024 14:52:17 Bought 2 CNXC @ 57.7 -115.40
04/03/2024 14:52:17 Bought 2 CNXC @ 57.7 -115.40
04/03/2024 14:54:00 Bought 6 CNXC @ 57.7 -346.20
Was adding before earnings. Day after earnings was an outside day, closing up $2.97, on almost
two and a half normal vol. Thought I was probably done buying. Wrong again.
Some notes from their call:
During the first quarter, we repurchased approximately 240,000 shares of our stock for approximately $22
million at an average price of approximately $90 per share
Given our confidence in our outlook and our future prospects, we are committed to making $100 million in
share repurchases between March 1, 2024, and the end of our fiscal year, approximately doubling the
capital return through share repurchases from the prior year. This will not stop us from rapidly reducing
leverage over the balance of 2024 as we committed when completed the Webhelp transaction.
Our non-GAAP EPS expectations for the full year remain in a range of $11.69 per share to $12.50 per share.
In terms of cash flow, we expect adjusted free cash flow of $700 million in 2024, inclusive of acquisition and
integration costs. This assumes no change to the amount of factored accounts receivable from the
beginning of the year. This will position us to further reduce our net leverage to approximately 2.5x adjusted
EBITDA by year-end, while committing to the enhanced share repurchase activity Chris mentioned earlier.
Our business outlook and cash flow expectations did not include any future acquisitions or impacts from
future foreign currency fluctuations. |
